TLPPF Financials: Telix Pharmaceuticals Ltd AI Analysis

Home

Stock

TLPPF

TLPPF Financial

Telix Pharmaceuticals Ltd

$8.93

1.59%

$0.14

At close: Mar 23, 16:00:00 GMT-4

$8.93

Post-market: Mar 23, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$8.79

Open

$8.75

Day's Range

$8.75 - $8.93

52 week range

$5.91 - $19.99

Volume

360

Avg.Volume

3.6K

Dividend yield

EPS (TTM)

-0.02

Market Cap

$3.0B

What is Telix Pharmaceutical Ltd.?

Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 1,120 full-time employees. The company went IPO on 2017-11-15. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

TLPPF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	803	803	516	332	103	7
Revenue Growth (YoY)	56%	56%	55%	222%	1,371%	40%
Cost of Revenue	421	421	197	129	42	2
Gross Profit	381	381	319	203	61	5
Selling, General & Admin	192	192	129	83	56	46
Research & Development	171	171	127	85	52	34
Operating Expenses	350	350	264	190	120	81
Other Non Operating Income (Expenses)	-27	-27	-19	-8	-4	-5
Pretax Income	-5	-5	37	2	-63	-80
Income Tax Expense	1	1	4	-1	3	0
Net Income	-7	-7	33	4	-67	-80
Net Income Growth	-121%	-121%	725%	-106%	-16%	82%
Shares Outstanding (Diluted)	338.55	337.88	345.18	323.71	310.64	282.2
Shares Change (YoY)	-7%	-2%	7%	4%	10%	10%
EPS (Diluted)	-0.02	-0.02	0.09	0.01	-0.21	-0.28
EPS Growth	-121%	-122%	651%	-106%	-24%	64%
Free Cash Flow	-73	-73	-3	7	-50	-60
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	47.44%	47.44%	61.82%	61.14%	59.22%	71.42%
Operating Margin	3.73%	3.73%	10.46%	3.61%	-56.31%	-1,085.71%
Profit Margin	-0.87%	-0.87%	6.39%	1.2%	-65.04%	-1,142.85%
Free Cash Flow Margin	-9.09%	-9.09%	-0.58%	2.1%	-48.54%	-857.14%
EBITDA	--	--	--	--	-53	-71
EBITDA Margin	--	--	--	--	-51.45%	-1,014.28%
D&A For EBITDA	--	--	--	--	5	5
EBIT	30	30	54	12	-58	-76
EBIT Margin	3.73%	3.73%	10.46%	3.61%	-56.31%	-1,085.71%
Effective Tax Rate	-20%	-20%	10.81%	-50%	-4.76%	0%

Follow-Up Questions

What are Telix Pharmaceuticals Ltd's key financial statements?



According to the latest financial statement (Form-10K), Telix Pharmaceuticals Ltd has a total asset of $1,163, Net loss of $-7

What are the key financial ratios for TLPPF?



Telix Pharmaceuticals Ltd's Current ratio is 1.55, has a Net margin is -0.87, sales per share of $2.37.

How is Telix Pharmaceuticals Ltd's revenue broken down by segment or geography?



Telix Pharmaceuticals Ltd largest revenue segment is Precision Medicine, at a revenue of 771,106,000 in the most earnings release.For geography, United States is the primary market for Telix Pharmaceuticals Ltd, at a revenue of 762,308,000.

Is Telix Pharmaceuticals Ltd profitable?



no, according to the latest financial statements, Telix Pharmaceuticals Ltd has a net loss of $-7

Does Telix Pharmaceuticals Ltd have any liabilities?



yes, Telix Pharmaceuticals Ltd has liability of 748

How many outstanding shares for Telix Pharmaceuticals Ltd?



Telix Pharmaceuticals Ltd has a total outstanding shares of 338.77

Telix Pharmaceuticals Ltd (TLPPF) Price

TLPPF Stock Price Chart